CD47 is an immune checkpoint protein that downregulates both the innate and adaptive anti-tumor 20 immune response via its counter receptor SIRPα. Biologics, including humanized CD47 monoclonal 21 antibodies and decoy SIRPα receptors, that block the SIRPα-CD47 interaction, are currently being 22 developed as cancer immunotherapy agents. However, adverse side effects and limited penetration of 23 tumor tissue associated with their structure and large size may impede their clinical application. We 24 2 recently developed a quantitative high throughput screening assay platform to identify small molecules 25 that disrupt the binding of SIRPα and CD47 as an alternative approach to these protein-based 26 therapeutics. Here, we report on the development and optimization of a cell-based binding assay to 27 validate active small molecules from our biochemical screening effort. This assay has a low volume, 28 high capacity homogenous format that relies on laser scanning cytometry (LSC) and associated 29 techniques to enhance signal to noise measurement of cell surface binding. The LSC assay is specific, 30 concentration dependent, and validated for the two major human SIRPα variants (V1 and V2), with 31 results that parallel those of our biochemical data as well as published studies. The LSC assay also 32 confirmed published studies, such as the inhibition of amino-terminal pyroglutamate formation in CD47 33 disrupts SIRPα binding. SIRPα-CD47 interaction could be quantitatively measured in live and fixed 34 tumor cells. Use of fixed cells reduces the burden of cell maintenance and provides stable cell 35 standards to control for inter-and intra-assay variations. We also demonstrate the utility of the assay 36 to characterize the activity of the first reported small molecule antagonists of the SIRPα-CD47 37
INTRODUCTION 42
Cancer arises in part when tumor cells acquire mechanisms to disrupt both innate and adaptive 43 immunity to evade immune surveillance [1] [2] [3] . Immune checkpoint inhibitors are being developed as a 44 therapeutic strategy to enable the immune system to eradicate neoplasia, especially disseminated 45 tumor cells [4, 5] . Antibodies to inhibit the adaptive immune checkpoints PD-1/PD-L1 and CTLA-46 4/(CD80, CD86) have proven to be remarkably efficacious in a subset of patients [6] [7] [8] [9] [10] . Chimeric T-47 cell receptors and dendritic cell vaccines are also promising treatment modalities to boost the adaptive 48 immune response [11, 12] . Another emerging strategy focuses on enhancing innate tumor immunity by 49 targeting the SIRPα-CD47 axis [13] . 50 51 CD47 is widely expressed on cells and binds to its counter-receptor SIRPα, which is expressed on the 52 surface of macrophages and antigen-presenting cells (APCs), to inhibit phagocytosis and antigen 53 presentation [14] [15] [16] [17] [18] . This is a basic mechanism of innate immune tolerance-the so called 'don't eat 54 me" signal. Increased expression of CD47 by tumor cells inhibits their phagocytosis, a crucial way in 55 which they evade immune surveillance [19] . Many preclinical studies have shown that abrogation of the 56 SIRPα-CD47 interaction, especially when combined with tumor targeting antibodies or 57 chemo/radiotherapy, promotes cancer cell death and improves survival [19] [20] [21] [22] [23] [24] [25] [26] [27] . Various biologic 58 agents targeting the SIRPα-CD47 axis, including monoclonal antibodies and decoy receptors, are in 59 early clinical development as cancer immunotherapies [28] [29] [30] [31] . Encouraging results for one of these 60 agents were recently observed in a phase 1b clinical trial [32] . 61
62
We have initiated a novel strategy to disrupt the SIRPα-CD47 protein-protein interaction (PPI) that is 63 focused on drug-like small molecules (SMs) [33] . In contrast to the large biologics, SM inhibitors can be 64 designed to specifically block the binding of CD47 to SIRPα without interfering with its other binding 65 partners, e.g. members of the thrombospondin and integrin families [34] . This strategy will allow the 66 SMs to serve as specific molecular probes of SIRPα-CD47 signaling in experimental models. Moreover, 67 along with the pharmacodynamic advantages and potential for oral delivery, such specificity may favor 68 their use as therapeutics by reducing adverse side effects. Recently, we developed a set of quantitative 69 high throughput screening (qHTS) assays and identified SMs that inhibit the SIRPα-CD47 70 interaction [33] . 71
72
In the present report, we describe a sensitive, high capacity, cell-based, SIRPα-CD47 binding assay 73
with characteristics that will enhance the identification of preclinical and clinical agents. It combines 74 5 Cell lines were Mycoplasma-free as determined with the MycoAlert mycoplasma detection kit (Lonza, 00
Walkersville, MD, USA) and were carried no more than 20 passages from the validated stocks. 01
02

Flow Cytometry Assay
03
Approximately 100,000 cells were harvested, washed with PBS, resuspended in 200 µL of PBS 04 containing 1% human serum albumin and 0.01% sodium azide (FACS Buffer, BD), and added to a 05 96-well round bottom plate for staining. SIRPa-biotin was added as indicated and incubated for 30 06 min at room temperature. Cells were then washed by centrifuging at 1000 x g for 5 min, supernatant 07 aspirated, and resuspended in 200 µL of FACS Buffer. Streptavidin-Alexa488 (SAV488) was then 08 added at 0.5 μg/mL for 30 min at room temperature after which the cells were washed again as 09 above. For non-biotin SIRPa competition studies, the non-biotin and biotin conjugated forms were 10 incubated with the cells at the same time at the indicated concentrations. For Anti-CD47 antibody 11 labeling studies, fluorochrome conjugated antibodies B6H12 and CC2C6 were used at 1 μg/mL final 12 concentration. Fluorochrome-labeled isotype control antibodies were used as negative controls for 13 nonspecific immunoglobulin binding. Cells were washed as above, samples were resuspended in 200 14 µL of FACS Buffer and measured on a FACS CALIBER II and Accuri C6 Flow Cytometer (BD 15 BioSciences). We adhered to the guidelines for the use of flow cytometry and cell sorting in 16 immunological studies. 17
Laser Scanning Cytometry Assay
18
The assay was conducted as in Table 1 , and all manipulation/incubations were subsequently carried 19 out at room temperature. Optimized reagent amounts for 384 and 1536 well plates are as in Table 2 . 20 DRAQ5-labeled cells were added to 384 or 1536 well plates using a multichannel pipet or a Multidrop 21 dispenser (ThermoFisher). Competing ligand/antibody or control mixed with SIRPa-biotin were added 22 to the cells using a multichannel pipet or Mosquito liquid handler (TTP Labtech). Following NAV488 23 addition and incubation, cell plates were imaged using the Mirrorball LSC according to Table 1 . For 6 measurements involving fixed cells, the cells were fixed in 4% paraformaldehyde for 30 min on ice, 25 washed and then stained as above. 26
Sequence Parameter
Value Description SEN177 treatment 38 A2058 cells were plated on day 0 in 6 well plates at 300,000 cells per well in fully supplemented RPMI 39 as described above. The cells were allowed to adhere overnight and then were treated with SEN177 40 (Sigma) with a constant DMSO (vehicle) level of 0.9%. The treatment was repeated 24 hours later. 24 41 hours after the second SEN177 treatment, the cells were harvested using trypsin and fixed (4% 42 paraformaldehyde for 30 min on ice) before being split into 3 samples for analysis in parallel using 43 SIRPa/LSC, CC2C6/flow cytometry, and B6H12/flow cytometry. Data represent the mean and standard 44 error of 3 biological replicates with 3 technical replicates of each biological replicate. 45
46
RESULTS
47
SIRPα binding to Jurkat cells detected by flow cytometry 48
We previously used SIRPα and CD47 recombinant proteins to develop a set of biochemical assays for 49 qHTS of SM libraries to identify inhibitors of the SIRPα-CD47 interaction [33] . The next step toward 50
identifying SIRPα-CD47 inhibiting SMs was to establish an assay that would enable us to test the ability 51 of lead compounds to inhibit SIRPα binding to CD47 naturally expressed by tumor cells. For this 52 purpose, we developed a model where the affinity for CD47 of a truncated biotin-tagged SIRPα, 53 hereafter referred to as SIRPα, was assessed on Jurkat T cells with [CD47(+)] or without [CD47(-)] 54 CD47 expression by flow cytometry (Fig. 1A) . SIRPα bound CD47(+) cells in a concentration-55 dependent manner, while no binding to CD47(-) cells was detected ( Fig. 1B-1C) . The specificity of the 56 interaction was demonstrated by both saturable binding ( Fig. 1D ) and competition with a non-biotin 57 
69
While flow cytometry is routinely used for cell-based ligand binding assays and immunoassays, it has 70 practical limitations with regard to the sample processing speed, reagent consumption, and the number 71
of samples that can be tested in a single experiment. To overcome these limitations, a cell-based 72
SIRPα-CD47 binding assay ideally would include a low cell/reagent consumption, large sampling 73 density for replicates and high-resolution concentration-response titrations. To satisfy these criteria, we 74 developed a binding assay using a LSC platform (Mirrorball, TTP Labtech). Early LSC-style assays 75 developed for cell-based cytokine and GPRC receptor fluorophore-labeled ligand binding were first 76 demonstrated on early prototype plate-based cytometers [35] . The current LSC platform utilizes 77 confocal optics that enable discrimination of cell-based fluorescence from bulk (unbound) fluorescence, 78 permitting a wash-free, homogeneous protocol [37] . Using the same reagents as in the conventional 79 flow cytometry assay described above, we optimized the LSC assay signal and robustness for plate 80 type, cell number, secondary detection reagent concentration, incubation time, and instrument settings 81 (Tables 1 and 2) . The staining strategy is as illustrated in the schematic drawing ( Fig. 2A) . 82
Representative data show the nuclear counter stain employed for cell detection (DRAQ5; Fig. 2B ) and 83 the Alexa488 channel that represents SIRPα binding via neutravidin-Alexa488 (NAV488; Fig. 2C) . EC50 value of 16 nM obtained in the optimized LSC assay (Fig. 3A) is ~100-fold lower (greater affinity) 01 than in the flow cytometry assay (see Fig. 1D ), most likely due to differences in the specific protocols 02 that affect reagent avidity (see Discussion). We next evaluated the binding affinity of CD47 to the most 03 common human SIRPα allelic variants, variants 1 and 2 (SIRPαV1 and V2). SIRPαV2 was two-fold 04 more potent than SIRPαV1 in binding to CD47 (Fig. 3B) To verify the CD47 specificity of the assay, we examined the binding of SIRPα to CD47(+) cells in the 15 presence of a CD47 blocking antibody, clone CC2C6, -an antibody selected for its ability to block both 16
SIRPαV1 and V2 binding to CD47 on CCRF-CEM cells [39] . In these assays, a fixed concentration of 17 SIRPαV1 (20 nM) was co-incubated with the competitor for CD47 binding (CC2C6, B6H12 or 18 recombinant CD47 as indicated). CC2C6 inhibited SIRPαV1 binding to Jurkat cells with an IC50 of 74 19 pM, comparable to the previously reported CD47 blocking activity of this antibody [40] (Fig. 4A) . 20
Another CD47 blocking antibody, B6H12, also disrupted the SIRPα-CD47 interaction (Fig. 4B) . The to inhibit SIRPαV1 binding to cell-expressed CD47 was also measured and found to be similar to 23 previously reported biochemical results (0.9 µM vs 0.8 µM, respectively) ( Fig. 4B) [42, 43] . Using a 24 similar competition assay, we measured the ability of non-biotin conjugated SIRPαV1 and SIRPαV2 to 25 antagonize the binding of their biotin-conjugated analogs. The IC50s of SIRPαV1 and SIRPαV2 to 26 native, cell surface expressed CD47 were 7.5 and 3.0 μM, respectively (Fig. 4C) . These data were 27 consistent with a previous report that SIRPαV1 is a relatively weaker binder (~2-fold) than SIRPαV2, 28 although the IC50 values we observed were ~5-fold higher (weaker inhibition) than the kD observed in Use of fixed cells in SIRPα-CD47 binding assay with LSC platform 42 We explored the possibility of further refining the assay to optimize its suitability for a drug development 43 campaign. Because fixed cells would be a stable source of CD47 for automated protocols and inter-44 day comparisons, we tested the effect of cell fixation on SIRPα-CD47 binding characteristics in our LSC 45 assay ( Fig. 5) . SIRPα bound similarly before and after cell fixation, (Fig. 5A) , consistent with a previous 46 report using flow-cytometry [44]. The EC50 was somewhat lower for the fixed cells compared to live 47 cells (1.3 nM vs. 4.6 nM). We also observed that DMSO (1%) had little effect on SIRPα binding in the 48 fixed-cell assay (Fig. 5B) , thus indicating that the assay could be used for testing the inhibitory activity 49 of SMs solubilized in DMSO. Lastly, we compared the activity of a known SIRPα-CD47 binding inhibitor 50 (CD47 blocking mAb B6H12) using fixed cells in the LSC-based assay to our biochemical assay in a 51 1536 well plate format ( Fig. 5C ) (as described in [33] ). The IC50 of B6H12 in the LSC assay was 6 nM 52 and 1 nM for 384 and 1536 well respectively, compared to 10 nM for the biochemical assay. The shift 53 in potency for the LSC assay in 384 (live cells) to 1536 (fixed cells) wells likely reflects the same shift 54 due to fixation as seen in Fig, 5A . Both LSC assay formats compare well to our biochemical screening 55 assay. Cell-based analysis of SM inhibitors previously identified in a CD47-SIPRα qHTS. 66 In our recent publication[33], we described the development of a series of biochemical assays for the 67 discovery of SIRPα-CD47 inhibiting SMs using qHTS. In order to characterize validated biochemical 68 hits and optimize them toward lead molecules, it is important to demonstrate their activity in cell-based 69 models. For this purpose, we used the LSC assay to measure SM antagonism of SIRPα binding to 70 CD47 naturally expressed on tumor cells and compared the activity of these qHTS active SMs to the 71 activity observed in the biochemical assay. Fig. 6A shows a representative set of chemical analogs 72 based on the parent compound identified from qHTS (NCGC00138783). These compounds illustrate a 73 typical attempt to establish a structure activity relationship to enable optimization of potency and drug-74 like properties via medicinal chemistry. Concentration-response curves for the SMs in the biochemical 75 and cell-based assays are presented in Fig. 6B and 6C LSC assay confirmed that CD47 post-translational modification is required for 87 SIRPα-CD47 binding.
88
Consistent with interactions inferred from the SIRPα-CD47 co-crystal structure [42, 43] , SIRPα-CD47 89 binding critically depends on a CD47 post-translational modification of its N-terminal glutamine to a 90 pyroglutamate [36] . This modification in tumor cells depends on the activity of glutaminyl cyclase 91 (QPCTL) and can be inhibited pharmacologically by the pan-glutaminyl cyclase inhibitory molecule 92 SEN177[45]. We used the LCS assay to validate and extend these findings by treating A2058 93 melanoma cells with SEN177 to inhibit QPCTL and block the N-terminal pyroglutamate modification of 94 CD47 (Fig. 7) . As in [36] , we observed a reduction in SIRPα binding after 48 h treatment with SEN177 95 (Fig. 7A) . This was also associated with a similar reduction in the reactivity of clone CC2C6 antibody, 96 whose epitope is known to be sensitive to the N-terminal pyroglutamate modification[39] (Fig. 7B) . 97
Total CD47 levels were not significantly affected as judged by a lack of SEN177 treatment-associated 98 changes in cell surface binding of the CD47 antibody clone B6H12, which is insensitive to N-terminal 99 pyroglutamate modification [36] (Fig. 7C) . In addition to validating the impact of the glutaminyl cyclase The final assay that we developed has a low volume, high capacity homogeneous format that, in 36 combination with our biochemical assay, will enable the screening thousands of compounds to identify 37 active SMs, develop structure activity relationships (SAR) and support the optimization of hits to leads 38 by a typical iterative medicinal chemistry campaign. We demonstrated that the assay is specific, 39 concentration dependent and works well for the two major human expressed variants of SIRPα (V1 and 40 V2). Results with our LSC assay parallel those obtained with our biochemical assay as well as the 41 previously published studies by others. Notably, we confirmed the recent findings that treatment of cells 42 with the glutaminyl transferase inhibitor, SEN177, blocked SIRPa binding ( Fig. 7 and Logtenberg et 43 al.). Furthermore, the LSC assay is capable of quantitatively measuring the SIRPα-CD47 interaction 44 in both live and fixed tumor cells; as a practical matter, this significantly reduces the cell culture burden 45 and allows for the use of stable, fixed cell standards to control for inter-and intra-assay variations. 46
Although we have focused here on SIRPα-CD47, the LSC-based cellular receptor ligand binding assay 47 is also applicable to other cell surface receptor-ligand or receptor-counter-receptor complexes 48 (including immune checkpoints), especially in situations where producing the recombinant receptor is 49 problematic or where its activity is significantly altered outside of the native cellular environment. 50
Because detection of binding signal in the LSC assay was targeted specifically to cells marked by a 51 nuclear stain and limited to the cell-containing focal plane by confocal optics, there was no need to 52 remove non-binding reagents by including washing steps. Under these conditions, SIRPα is presented 53 to CD47 on the cells as a multimeric reagent bound to tetrameric NAV. This presumably contributed 54 to a stronger binding affinity of SIRPα and CD47 relative to measurements in a standard flow cytometry 55 format where SIRPα is first presented as a monomer and non-bound reagent is removed by washing 56 before exposure to SAV. While the higher avidity of SIRPα-CD47 interaction in the LSC assay would 57 make it more difficult to observe the inhibitory effect of compounds having substantially lower potency, 58
we were able to detect specific inhibition by a number of compounds that were first identified in our 59 qHTS of libraries containing tens of thousands of SMs. Thus, we were able to validate active SMs from 60 our cell-free screen and follow up by testing structurally related analogs to begin to determine SAR for 61 the compound series. 62
63
The binding of recombinant CD47 with SIRPα was previously determined using SPR with immobilized 64 CD47. Here we titrated soluble CD47 to measure its ability to bind soluble SIRPα and antagonize the 65 interaction of the latter with cell-expressed CD47. Using this system, we demonstrated similar affinities 66 when CD47 and SIRPα were permitted to interact in solution as compared to their interaction when 67 CD47 was immobilized for an SPR assay (Fig. 4B, C) . 68
69
The ability of SIRPα to bind CD47 on formalin-fixed cells raises the possibility that this reagent also 70 might bind specifically to CD47 in formalin-fixed, paraffin-embedded tissue specimens. If this were 71 borne out, then such an assay could be used to identify tumors with high SIRPα-CD47 binding capacity 72
and therefore likely to be responsive to immunotherapy targeting this interaction. The detection of high 73
affinity SIRPα binding on tumor cells may prove to be a better indicator of response to therapy than 74 measures of CD47 mRNA or protein expression. 
